B
Bull
Bull · 25%ENTO
$0.57
情境價格
$2.990
+0.158 (+5.28%)收盤時
Loading chart…
- High
- 3.750
- Open
- 3.170
- VWAP
- 3.19
- Vol
- 896.84K
- Mkt Cap
- —
- Low
- 2.840
- Amount
- 2.86M
- EV/EBITDA, TTM
- 0.00
GridAI Technologies Corp., formerly Entero Therapeutics, Inc., offers a grid-edge, artificial intelligence (AI)-driven software and control platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems. It applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The Company also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
估值指標
The current forward P/E ratio for Entero Therapeutics Inc (ENTO) is -0.27, compared to its 5-year average forward P/E of -3.68.
Alphio AI Price Scenarios for ENTO
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
2.012-01NASDAQ.COMBiotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet
4.511-28NASDAQ.COMEntero Therapeutics Shares Rise 5% Before Transitioning to GridAI
7.511-19TipRanksNASDAQ: ENTO Secures Hyperscale Agreement in Texas as Its $50M Industrial Software Platform Joins the AI Competition
2.008-28BenzingaFive Biotech Stocks Showing Significant Momentum
9.008-17TipRanksUpcoming Stock Splits This Week (August 18 to August 22) – Stay Invested
ENTO FAQ — answered by Alphio AI
GridAI Technologies Corp., formerly Entero Therapeutics, Inc., offers a grid-edge, artificial intelligence (AI)-driven software and control platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems. It applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The Company also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。